DailyIQ
Last updated2 minutes ago

LLY·Eli Lilly and Company

$1252.39
+43.65 (+3.61%)
Overnight$1252.99+0.60 (+0.05%)
High
$1,275.88
Open
$1,235.04
Market Cap
1.14T
52W High
$1,292.65
Low
$1,213.76
P. Close
$1,252.39
P/E
42.56
52W Low
$776.00
Fwd P/E
25.46
DailyIQ Est.
$1390.54
Inst. Ownership
35.7%
Short Interest
0.72%
Days to Cover
2.9
Div. Yield
0.53%
Next Ex-Div
~Nov 13
Div. Growth
11+ yrs
NewEarnings release, scored · filed Aug 5, 2026Guidance raised · tone +1.9 vs prior release · 58 lines scoredSee the breakdown
Technical Score (1D)
76
BULLISH
News Sentiment
57
BULLISH
On Oct 13, Eli Lilly disclosed exploratory Phase 3b data from the TOGETHER‑PsO trial, showing that the combination of Taltz and Zepbound produced a broader array of immune and metabolic biomarker changes than Taltz alone in adults with moderate‑to‑severe plaque psoriasis and obesity or overweight. The enhanced biomarker response emerged as early as week 12, suggesting a potential immunometabolic link between psoriasis and obesity. These findings could enable Lilly to develop new treatment strategies that integrate its immunology and obesity portfolios within overlapping patient populations. On the same day, Lilly reported that its net income more than doubled to $20.6 billion, compared with Bristol Myers Squibb’s $7.1 billion. The earnings jump reflected Lilly’s expansion into weight‑loss and metabolic health, positioning it as a growth leader in the biopharma sector. The contrast in performance reshaped the value‑versus‑growth debate, favoring Lilly as a higher‑growth option for investors.
LOW TARGET
$930 -25.7%
2 analysts
MEAN TARGET
$1328 +6.1%
20 analysts
HIGH TARGET
$1600 +27.8%
17 analysts
PRICE RANGE
$930.00 - $1600.00
SB / B / H / S / SS
11/19/7/1/1
DAILYIQ EST.
$1390.54 (+11.1%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
Symbol
LLY
Description
Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, and commercialization of human medicines. The company's core business revolves around a diverse portfolio of treatments addressing significant health challenges, including diabetes, oncology, and immunological disorders. Key products include diabetes medications like Mounjaro and Trulicity, as well as oncology drugs such as Verzenio. Eli Lilly also offers therapies for conditions like rheumatoid arthritis, psoriasis, and migraine, demonstrating a broad therapeutic focus. Strategic collaborations with various partners, including Incyte and Boehringer Ingelheim, support the company's research and development efforts, driving innovation in the pharmaceutical landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
16,438.707 shares
$19.3M
Alvarez Ralph-
Award/Grant10.659 shares2026-09-21
Fyrwald J Erik-
Award/Grant8.513 shares2026-09-21
LUCIANO JUAN R-
Award/Grant13.664 shares2026-09-21
Sulzberger Gabrielle-
Award/Grant4.257 shares2026-09-21
Seymour MelissaEVP, Global Quality
Gift12 shares2026-09-09
78/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
31.7%
Revenue CAGR
7.2%
Current Ratio
1.58x
Debt / Equity
1.60x
Return on Equity
77.8%
Earnings Summary
Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, and commercializing human medicines across diabetes, oncology, and immunology, with key products such as Mounjaro, Trulicity, and Verzenio. In the highly competitive drug manufacturing sector, Lilly leverages strategic collaborations to accelerate innovation. Recent quarterly results show a consistent upward trajectory: Q4 2024 EPS of $5.32 beat the $5.07 estimate while revenue reached $13.53 billion; Q1 2025 EPS dipped to $3.34 below the $3.54 estimate with revenue $12.73 billion, reflecting a seasonal slowdown; Q2 2025 EPS of $6.31 exceeded the $5.59 estimate and revenue climbed to $15.56 billion; Q3 2025 EPS of $7.02 beat the $5.89 estimate with revenue $17.60 billion; Q4 2025 EPS of $7.54 surpassed the $6.74 estimate and revenue hit $19.29 billion; Q1 2026 EPS of $8.55 outpaced the $6.79 estimate and revenue rose to $19.80 billion; Q2 2026 EPS of $8.38 exceeded the $6.07 estimate and revenue reached $22.97 billion. The company has consistently beat estimates in the last five quarters, with revenue growth accelerating from 12% in Q4 2024 to 18% in Q2 2026. Historically, Lilly has maintained a YoY revenue growth rate above 10% over the past three years, with EPS growth outpacing revenue in most periods, indicating effective cost management and pricing power. Recent news highlights exploratory Phase 3b data from the TOGETHER‑PsO trial showing enhanced biomarker responses for the Taltz and Zepbound combination, suggesting potential expansion into obesity and metabolic indications; the company also reported net income more than doubling to $20.6 billion, underscoring its growth trajectory.

EPS

EstBeatMiss
$5.15$6.11$7.07$8.03$8.99Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$7.16 - -
Q2'26$6.07$8.38+38.1%
Q1'26$6.79$8.55+25.9%
Q4'25$6.74$7.54+11.9%
Q3'25$5.89$7.02+19.2%
Q2'25$5.59$6.31+12.9%

Revenue

EstBeatMiss
$14.4B$16.9B$19.3B$21.7B$24.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$22.7B - -
Q2'26$20.9B$23.0B+9.8%
Q1'26$17.8B$19.8B+11.1%
Q4'25$18.1B$19.3B+6.4%
Q3'25 - $17.6B -
Q2'25 - $15.6B -

Market Data

LLY Stock Snapshot

BULLISH76/100
$1252.99+$0.60 (0.0%)
Market cap
1.14T
P/E ratio
42.6
Day range
$1213.76 – $1275.88
News sentiment
57/100 · Neutral
Analyst target
$1328.05 (+6.0%)
Consensus
Buy · 39 analysts
52-week range+61.5% off low · -3.1% from high
$776.00$1292.65
Price $1252.99 DailyIQ Est. $1390.54

Trend, momentum and range position line up bullish on LLY at the moment. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.

Behaviour On Record

What LLY's own history says about today's numbers

Realized volatility (21d)
25.2% 57th pct
Below its peak
-2.2%
vs 200-day average
+16.1%
Up days (1y)
50%

Eli Lilly and Company is currently running 25.2% annualised volatility over the last 21 sessions. Measured against LLY's own 13 years of daily returns rather than a market-wide average, that is the 57th percentile — close to its own typical level, against a typical reading of 23.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

LLY is trading -2.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.0%, and the deepest was -32.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +16.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 67th percentile — a somewhat wider gap than its own norm. Over the past year LLY closed higher on 50% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 14 years of records, LLY finished the month higher 9 of 14 times, with a median return of +1.9% and an average of +1.0%. Its strongest month historically has been June at +5.6% on average, its weakest July at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: LLY has opened more than 2% away from the prior close in 72 of 3,268 sessions (2.2% of the time), with the largest gaps running +11.5% and -5.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, LLY moved an average of 3.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.0% and a largest of -6.1%.

All figures computed from 3,269 daily closes between 2013-10-16 and 2026-10-15, split-adjusted, recomputed daily. Percentiles are against LLY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of LLY's sector?

Eli Lilly and Company sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#1 of 12
Sector state
Leading
Sector rotation score
100

Options Market

What is the options market pricing for LLY?

CallsPuts

For Eli Lilly and Company's nearest expiry (2026-10-16, 1 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.70), with at-the-money implied volatility around 31.6%. The options market is pricing roughly a ±1.6% move by that expiry — a range of about $1243.50–$1284.16.

Put/call ratio (2026-10-16)
0.70
ATM implied volatility
31.6%
Total open interest
38,555
Expected move by 2026-10-16
±1.6% ($1243.50–$1284.16)

Analyst Rating Changes

Are analysts turning bullish or bearish on LLY?

RBC Capital most recently reiterated its rating on Eli Lilly and Company to Outperform on Oct 12, 2026 with a price target of $1500. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026RBC CapitalReiteratedOutperform$1500
Oct 8, 2026Cantor FitzgeraldMaintainedOverweight$1410 → $1440
Oct 7, 2026Morgan StanleyMaintainedOverweight$1419 → $1430
Sep 28, 2026JP MorganMaintainedOverweight$1400 → $1500
Sep 22, 2026TD CowenReiteratedBuy$1250
Sep 18, 2026GuggenheimMaintainedBuy$1273 → $1284
Sep 10, 2026HSBCMaintainedReduce$850 → $940
Aug 7, 2026Truist SecuritiesMaintainedBuy$1370 → $1376
Aug 6, 2026Wells FargoMaintainedOverweight$1280 → $1330
Aug 6, 2026Cantor FitzgeraldMaintainedOverweight$1350 → $1410
Jul 15, 2026CitigroupMaintainedBuy$1500 → $1600
Jul 14, 2026BernsteinMaintainedOutperform$1300 → $1385

Earnings Release, Scored

What did Eli Lilly and Company's latest earnings release say?

Filed Aug 5, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone74.9/ 100+1.9 vs prior release
Hedging words0.09per 100 words-0.31 vs prior release
Tone, last 2 releasesScale 50–80

Most important lines

  1. 1

    Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50.

    Guidance raisedNew this quarter
  2. 2

    "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance," said David A. Ricks, Lilly chair and CEO.

    Guidance raised
  3. 3

    In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of $2.78 (at the midpoint of the range) due to strong underlying business growth, offset by $3.03 associated with the Q2 acquired IPR&D charges from recent business development activity:

    Guidance raisedNew this quarter

Peers & ETF holders

LLY peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

57/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Eli Lilly reported a more than two‑fold increase in net income, reaching $20.6 billion, compared with Bristol Myers Squibb’s $7.1 billion. The earnings jump reflects Lilly’s expansion into weight‑loss and metabolic health, positioning it as a growth leader in the biopharma sector. The performance contrast reshapes the value‑versus‑growth debate, favoring Lilly as a higher‑growth option for investors. The data suggest a shift in investor sentiment toward Lilly’s growth trajectory.
What did this article say?
Eli Lilly disclosed exploratory Phase 3b data from the TOGETHER‑PsO trial, showing that the combination of Taltz and Zepbound produced a broader array of immune and metabolic biomarker changes than Taltz alone in adults with moderate‑to‑severe plaque psoriasis and obesity or overweight. The enhanced biomarker response emerged as early as week 12, suggesting a potential immunometabolic link between psoriasis and obesity. These findings could enable Lilly to develop new treatment strategies that integrate its immunology and obesity portfolios within overlapping patient populations.
What did this article say?
Eli Lilly closed down 1.04% on Oct 13, falling more than the broader market. The drugmaker’s shares had risen 3.9% over the past month, but the day’s decline was noted as a potential warning ahead of its earnings release on Oct 29. Analysts project a 7.41% EPS increase and a 25.59% revenue rise for the quarter, suggesting a positive outlook despite the short‑term dip.
What did this article say?
The article discusses a selection of biotech companies deemed attractive for investors in October 2026, emphasizing those with solid balance sheets and reasonable valuations amid rising U.S. interest rates. Eli Lilly (LLY) is mentioned as one of the highlighted stocks, positioned as a potential addition to a watchlist. The piece outlines the broader market context of higher borrowing costs and the preference for financially robust medical researchers. It serves as a guide for investors to evaluate whether LLY fits their investment criteria. No specific financial guidance or performance metrics for LLY are provided.
What did this article say?
Eli Lilly (LLY) reported new data on its obesity drug Zepbound, the triple agonist retatrutide, and the diabetes candidate Foundayo, reinforcing investor confidence. The company also announced approvals for Jaypirca and Olumiant, and expanded its partnership with Gate Bioscience. Despite a brief 90‑day decline, LLY's year‑to‑date share price rose 8.26% and total shareholder return reached 37.6% over 12 months. These developments suggest sustained long‑term momentum for the company's pipeline.
What did this article say?
Bank of America Securities reduced Eli Lilly’s (LLY) price target from $1,344 to $1,341 while keeping a buy rating. The adjustment reflects a modest reassessment of the company’s valuation. No change was made to the overall recommendation, and the average analyst rating remains overweight. The move signals a slight headwind but does not alter the fundamental outlook for LLY.
What did this article say?
Eli Lilly reported a 48% revenue increase in the second quarter of 2026 and lifted its annual outlook. The company’s tirzepatide drugs Mounjaro and Zepbound drove the growth, with Mounjaro alone generating $9.9 billion and Zepbound $4.9 billion. Despite the strong earnings, the stock trades at a forward P/E of 30.94, below its five‑year average of 45.59, raising questions about valuation and future pricing pressure. Non‑GAAP gross margin reached 86.3%, supported by lower production costs and a higher‑margin product mix. The announcement signals robust sales momentum but also highlights potential valuation concerns as price cuts could erode margins.
What did this article say?
On October 9, Eli Lilly (LLY) appeared on Zacks.com’s list of most searched stocks, reflecting heightened investor interest. Over the preceding month, LLY shares had risen 4.2 %, outperforming the S&P 500 composite and the large‑cap pharmaceuticals sector. The article notes that earnings estimate revisions are the primary driver behind such trending behavior, suggesting that analysts’ expectations may be improving. While no new product or regulatory milestone was announced, the increased attention could support a modest upward bias in the near term.

Technical Analysis

Real-time indicators across multiple timeframes

76
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $399.17B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy81,965,9748.45%$88.09B2026-01-29
BlackRock, Inc.▲ Buy67,540,4006.96%$81.01B2026-08-07
FMR LLC (Fidelity)▲ Buy28,462,4752.93%$34.14B2026-08-13
Capital Research Global Investors▼ Sell20,873,1402.15%$25.04B2026-08-12
Geode Capital Management, LLC▲ Buy20,310,8582.09%$24.28B2026-08-12
Morgan Stanley▲ Buy16,226,3981.67%$19.46B2026-08-13
Capital World Investors▲ Buy15,902,6421.64%$19.08B2026-08-12
JPMorgan Chase & Co▼ Sell12,598,5241.30%$15.50B2026-08-12
Norges Bank▼ Sell11,471,4131.18%$13.76B2026-08-12
Bank of America Corp▲ Buy11,274,2431.16%$13.52B2026-08-14
Wellington Management Group LLP▼ Sell10,998,9531.13%$13.19B2026-08-14
Northern Trust Corp▼ Sell8,796,8660.91%$10.55B2026-08-13
Goldman Sachs Group Inc▲ Buy7,652,9600.79%$9.18B2026-08-14
Fisher Asset Management, LLC▲ Buy5,063,5160.52%$6.07B2026-08-04
Wells Fargo & Company▲ Buy4,646,1190.48%$5.57B2026-08-14
Invesco Ltd.▲ Buy3,694,1520.38%$4.43B2026-08-14
Janus Henderson Group plc▼ Sell4,347,3940.45%$3.98B2026-05-18
AllianceBernstein L.P.▼ Sell4,261,3850.44%$3.92B2026-08-14
Neuberger Berman Group LLC▼ Sell1,697,0610.17%$2.04B2026-08-13
Citigroup Inc▲ Buy1,199,0530.12%$1.44B2026-08-03
AQR Capital Management LLC▲ Buy1,035,6050.11%$1.24B2026-08-14
Citadel Advisors LLC▲ Buy945,4560.10%$1.13B2026-09-02
Prudential Financial Inc▲ Buy734,1480.08%$880.56M2026-08-12
Adage Capital Partners GP, L.L.C.▼ Sell726,1990.07%$871.02M2026-08-14
Polen Capital Management LLC▼ Sell666,9120.07%$799.91M2026-08-04
Q2 2026 flow:7.63M sh bought ($9.15B)8.60M sh sold ($10.30B)net -973.7K sh (−$1.16B)
Congressional Trading Activity
25 disclosed trades · ~$291.5K est. traded value · 11 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Dan NewhouseHouseWA04▼ Sell$1K - $15K2026-07-102026-07-17
Michael RulliHouseOH06▼ Sell$1K - $15K2026-07-012026-08-07
Gilbert CisnerosHouseCA31▲ Buy$50K - $100K2026-06-102026-07-02
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-04-142026-05-08
Elizabeth FletcherHouseTX07▼ Sell$1K - $15K2026-04-082026-05-01
Byron DonaldsHouseFL19▲ Buy$1K - $15K2026-04-022026-05-13
Alan ArmstrongSenateOK▼ Sell$1K - $15K2026-03-272026-07-21
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-02-262026-03-06
Angus KingSenate-▼ Sell$1K - $15K2026-02-132026-03-24
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-02-092026-02-20
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-01-162026-02-02
Michael RulliHouseOH06▲ Buy$1K - $15K2026-01-022026-08-07
Angus KingSenate-▲ Buy$1K - $15K2025-12-292026-01-26
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
David J. TaylorHouseOH02▼ Sell$1K - $15K2025-12-102025-12-19
Michael RulliHouseOH06▼ Sell$1K - $15K2025-12-022026-08-07
John BoozmanSenateAR▼ Sell$1K - $15K2025-11-212026-08-24
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2025-10-242025-11-04
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
John BoozmanSenateAR▲ Buy$1K - $15K2025-08-222025-09-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
David J. TaylorHouseOH02▲ Buy$15K - $50K2025-08-142025-09-02
John BoozmanSenateAR▲ Buy$1K - $15K2025-08-112025-09-12